Lipocine Inc. — FY2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016; filed March 6, 2017. Lipocine is a pre-commercial specialty pharmaceutical company developing oral drug-delivery products for men’s and women’s health. It reported no product sales revenue and depends on financing to fund development.
Financial performance and position
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | No revenue reported | No revenue reported |
| Research and development expense | $8.1 million | $12.6 million |
| General and administrative expense | $10.4 million | $5.8 million |
| Restructuring costs | $0.7 million | None |
| Operating loss | $19.2 million | $18.4 million |
| Net loss | $19.0 million | $18.2 million |
| Basic and diluted loss per share | $1.04 | $1.11 |
| Cash, cash equivalents and marketable securities | $26.8 million | $44.8 million |
| Operating cash used | $18.3 million | $15.4 million |
| Total liabilities | $1.3 million | $3.4 million |
Gross and operating margins are not meaningful because the company had no revenue. The balance sheet reports no borrowings; liabilities consisted of accounts payable and accrued expenses. Accumulated deficit was $105.4 million. Fourth-quarter 2016 operating loss was $3.0 million and net loss was $3.0 million, compared with fourth-quarter 2015 operating loss of $4.7 million and net loss of $4.6 million.
Changes versus prior year
- Net loss widened by $0.8 million. R&D expense fell by $4.5 million, mainly because LPCN 1021’s pivotal Phase 3 trial was completed and the 2015 NDA filing fee did not recur; this was offset by higher manufacturing and validation costs.
- G&A increased by $4.6 million, reflecting pre-commercialization spending, legal costs and personnel costs. The company recorded $0.7 million in restructuring charges and reduced its workforce by ten positions during 2016.
- Cash, cash equivalents and marketable securities declined by $18.0 million. Operating cash use increased, while 2015 financing had included $32.4 million of net equity proceeds; 2016 financing was principally stock-option exercises.
Business outlook, risks and unusual items
- LPCN 1021: The FDA issued a Complete Response Letter on June 28, 2016, citing a mismatch between the proposed real-world dose-titration approach and the pivotal trial. FDA indicated that a dosing regimen would need clinical validation before resubmission. Two Phase 3 studies were underway: dosing validation and dosing flexibility, each planned for about 100 participants over 24 days. Top-line results were expected in 2Q 2017. Management estimated approximately $8.8 million in additional LPCN 1021 development and manufacturing costs; approval is not assured.
- Other candidates: LPCN 1111 completed a Phase 2b dose-finding study; an FDA End-of-Phase 2 meeting was anticipated in 2H 2017. LPCN 1107 completed dose-selection work and FDA development-plan discussions; the company planned to submit a Phase 3 protocol through a Special Protocol Assessment in 1H 2017. A conventional trial design could require about 1,100 subjects per arm, although an adaptive design was under consideration.
- Liquidity: Management believed existing resources could fund projected operations for at least the next 12 months, and through December 31, 2017, but said additional capital would be needed to support longer-term development and commercialization. There was no credit facility or committed capital source. Funding shortfalls could delay, reduce or stop programs.
- Subsequent financing authorization: On March 6, 2017, Lipocine entered an at-the-market sales agreement allowing up to $20 million of common stock sales, with a 3% sales commission. Sales are optional but could dilute existing holders.
- Key operating risks: The business depends heavily on LPCN 1021 and regulatory outcomes; TRT faces safety, labeling, reimbursement and competitive uncertainty. Lipocine also relies on a single TU supplier and Encap as sole LPCN 1021 capsule manufacturer. Commercialization would require additional capabilities or partners.
- Litigation and IP: Securities class-action lawsuits related to LPCN 1021 disclosures were pending; management said it would defend them and did not record a contingency accrual. Clarus’s infringement suit was dismissed in October 2016, but could be refiled if LPCN 1021 is approved and marketed. A related patent interference proceeding remained pending.
- Accounting and controls: KPMG issued an unqualified audit opinion. Management reported effective disclosure controls and internal control over financial reporting at year-end. No off-balance-sheet arrangements were reported.
Most important facts for investors to verify
- Whether the dosing-validation and dosing-flexibility studies met FDA expectations and enabled an LPCN 1021 NDA resubmission.
- Updated cash runway, actual cash burn and whether equity issuance under the $20 million ATM agreement has occurred.
- Phase 3 design, cost, timing and financing needs for LPCN 1107, and progress toward LPCN 1111’s next regulatory step.
- Any changes in TRT safety requirements, labeling, market demand, reimbursement or competitive launches.
- Developments in the securities litigation, patent interference and Clarus’s potential infringement claim, as well as continuity of critical suppliers and manufacturing.